T2	outcome 1486 1489	DFS
T3	outcome 1505 1507	OS
T4	outcome 1291 1349	number of patients with positive axillary nodes at surgery
T5	outcome 1204 1232	complete pathologic response
T6	intervention 70 102	doxorubicin and cyclophosphamide
T7	control 108 133	doxorubicin and docetaxel
T8	eligibility 459 618	patients with histologic-proven breast cancer with primary tumours > or = 3 cm, inflammatory or locally advanced disease, and no evidence of distant metastases
T11	total-participants 1140 1143	363
T12	intervention-participants 1180 1183	181
T13	control-participants 1196 1199	182
T14	iv-bin-percent 1249 1252	16%
T15	cv-bin-percent 1264 1267	12%
T16	iv-bin-percent 1362 1365	61%
T17	cv-bin-percent 1373 1376	66%
T19	outcome 1610 1626	clinical benefit
T1	outcome 1520 1526	Deaths
